Keyphrases
Schizophrenic Patients
100%
Schizophrenia
74%
Patients with Schizophrenia
37%
Negative Symptoms
19%
Lithium
17%
First-episode Psychosis
16%
Interleukin-1β
13%
Cytokine Production
12%
Neutrophils
12%
Olanzapine
12%
Treatment-resistant Schizophrenia
11%
Lithium Carbonate
11%
Positive Symptoms
11%
Anticardiolipin Antibodies
11%
Hallucinations
11%
Schizophrenia Symptoms
11%
Psychosis
10%
Psychiatric Patients
9%
Mononuclear Cells
9%
Healthy Controls
9%
Peripheral Blood Mononuclear Cells
9%
Depressed Patients
9%
Chronic Schizophrenia
9%
Antipsychotics
8%
Peripheral Blood
8%
Clozapine
8%
Cancer Morbidity
8%
Fluvoxamine
8%
New Immigrants
8%
Obstetric Complications
8%
Interleukin-3
8%
Quetiapine
8%
Mental Illness
8%
Major Depressive Disorder
7%
Haloperidol
7%
Interleukin-1 Receptor Antagonist (IL-1Ra)
7%
DNA Damage
7%
Healthy Relatives
7%
First-night Effect
7%
Autoantibodies
6%
Schizoaffective Disorder
6%
Age-matched
6%
Negative Syndrome
6%
Lithium Treatment
6%
Recovery of RNA Synthesis
6%
Chlorpromazine
6%
Drug-free
5%
Israeli
5%
Tolerability
5%
Alcohol Abuse
5%
Neuroscience
Dementia Praecox
86%
Typical Antipsychotic
23%
Negative Syndrome
22%
Positive Syndrome
19%
Cytokine Production
12%
Cardiolipin Antibody
12%
Major Depressive Disorder
11%
Interleukin 1
11%
Peripheral Blood Mononuclear Cell
10%
Rapid Eye Movement Sleep
10%
Lithium Carbonate
9%
Olanzapine
8%
Interleukin 3
8%
Fluvoxamine
8%
Receptor Antagonist
7%
Autoantibodies
6%
Antioxidant
6%
Placebo
6%
Sleep Time
5%
Phagocytosis
5%
Chemotaxis
5%
Neuroblastoma
5%
Cell Line
5%
Pharmacology, Toxicology and Pharmaceutical Science
Typical Antipsychotic
29%
Antipsychotic
20%
Negative Syndrome
18%
Symptom
14%
Positive Syndrome
13%
Lithium Carbonate
12%
Quetiapine
12%
Olanzapine
12%
Superoxide
12%
Infection
9%
Fluvoxamine
8%
Clozapine
8%
Malignant Neoplasm
8%
Antioxidant
7%
Pharmacotherapy
6%
Placebo
6%
Inflammation
6%
Tumor Necrosis Factor
6%
Schizoaffective Psychosis
6%
Selective Serotonin Reuptake Inhibitor
5%
Disease
5%
Psychosis
5%
Tardive Dyskinesia
5%
Ethanol
5%
Tolerability
5%
Ultraviolet Irradiation
5%
Atypical Antipsychotics
5%
